| Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia (NCT05317390) | Massachusetts Eye and Ear Infirmary | 2022-06-01 |
| Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy (NCT05116813) | Addex Pharma S.A. | 2021-10-25 |
| Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia (NCT04912115) | PharmaTher Inc. | 2021-10-05 |
| Comparison of Open Chain Kinetic Exercises and Forward Head Posture Correction in Type II Scapular Dyskinesia (NCT05044572) | Riphah International University | 2021-09-15 |
| Effects of Music Beat on Motor Function in Individuals At Risk for Psychotic Onset and Schizophrenia Patients (NCT04929795) | Dr WANG Shumei | 2021-08-11 |
| Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy (NCT04857359) | Addex Pharma S.A. | 2021-08-06 |
| Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components (NCT04377945) | Bukwang Pharmaceutical | 2021-04-28 |
| Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia Patients (NCT04553835) | Dr WANG Shumei | 2020-08-31 |
| Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia (NCT04351360) | Institut National de la Santé Et de la Recherche Médicale, France | 2020-05-15 |
| Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic Onset (NCT04086160) | Dr WANG Shumei | 2019-08-22 |
| A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia (NCT03956979) | Contera Pharma | 2019-07-22 |
| A Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson's Disease (NCT04453995) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2019-01-05 |
| Effect of the Visual Information Change in Functional Dystonia (NCT03270189) | Fondation Ophtalmologique Adolphe de Rothschild | 2017-09-18 |
| An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease (NCT03034538) | The Cooper Health System | 2016-04-08 |
| Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia (NCT02589340) | Oregon Health and Science University | 2016-01-01 |
| Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias (NCT01491529) | Novartis Pharmaceuticals | 2012-04-01 |
| Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias (NCT01491932) | Novartis Pharmaceuticals | 2012-03-01 |
| Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias (NCT01385592) | Novartis Pharmaceuticals | 2011-11-01 |
| Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease (NCT01474421) | Novartis Pharmaceuticals | 2011-09-15 |
| Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease (NCT00986414) | Novartis | 2009-09-01 |
| Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects (NCT00360568) | AbbVie (prior sponsor, Abbott) | 2009-06-01 |
| Effects of Talampanel on Patients With Advanced Parkinson's Disease (NCT00036296) | Teva Branded Pharmaceutical Products R&D, Inc. | 2006-12-01 |
| Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1) (NCT00467597) | US Department of Veterans Affairs | 2006-04-01 |
| Levetiracetam Treatment of L-dopa Induced Dyskinesias (NCT00076674) | National Institute of Neurological Disorders and Stroke (NINDS) | 2004-01-01 |
| Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's (NCT00363727) | GlaxoSmithKline | 2003-12-01 |
| Study of LY300164 for the Treatment of Parkinson's Disease (NCT00004576) | National Institute of Neurological Disorders and Stroke (NINDS) | 2000-02-01 |